AI Biotech Sees New Funding and Deals
The AI-driven drug discovery space is heating up with fresh capital and strategic partnerships. Cardiff-based Antiverse raised $9.3 million to scale its antibody discovery platform for "undruggable" diseases. Meanwhile, Senhwa Biosciences signed a major deal with Y Combinator-backed CellType to reshape immunotherapy using AI, underscoring investor confidence in the sector.
Antiverse's platform specifically targets complex proteins like G-protein coupled receptors (GPCRs) and ion channels, which are considered "undruggable" by traditional methods. The new $9.3 million Series A, led by Soulmates Ventures, brings the company's total funding to over $20 million and will be used to scale these partnerships and advance its own antibody programs toward in vivo studies. The collaboration between Senhwa and CellType is centered on the drug Silmitasertib (CX-4945), a first-in-class CK2 inhibitor. Foundational research for the partnership involved Google DeepMind and Yale University, where an AI model screened over 4,000 compounds and first identified CX-4945's novel immune-modulatory potential. CellType's proprietary AI applies large language models to single-cell gene expression data to decode the complex tumor microenvironment. The model predicted that CX-4945 could make immunologically "cold tumors" visible to the immune system by significantly enhancing antigen presentation, a hypothesis later validated in lab studies at Yale. This AI-driven approach is a key trend in an industry where nearly 90% of drug candidates fail in clinical trials. The AI in drug discovery market is projected to grow substantially, with partnerships in the sector showing a compound annual growth rate of over 60% since 2018, signaling a major shift from conventional R&D. For machine learning engineers, the technical challenges involve creating generative models for *de novo* molecule design and applying transformers to biological data, similar to CellType's use of LLMs. Antiverse's platform combines machine learning with cell line engineering for rapid iteration between computational design and lab validation. Y Combinator's backing of CellType (Winter 2026 batch) highlights a growing trend of tech accelerators investing heavily in biotech. This convergence of deep tech and life science aims to drastically shorten development timelines and reduce the high costs associated with bringing new drugs to market.
